Statements (42)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:age |
9 to 45 years
|
| gptkbp:approvalYear |
2014
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:J07BM03
|
| gptkbp:contains |
aluminum adjuvant
recombinant L1 proteins |
| gptkbp:contraindication |
severe allergic reaction to previous dose
hypersensitivity to yeast |
| gptkbp:dosingSchedule |
2 or 3 doses depending on age
|
| https://www.w3.org/2000/01/rdf-schema#label |
Gardasil 9
|
| gptkbp:includedIn |
gptkb:WHO_Model_List_of_Essential_Medicines
|
| gptkbp:indication |
prevention of anal cancer
prevention of cervical cancer prevention of genital warts prevention of vaginal cancer prevention of vulvar cancer |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:protectedBy |
HPV types 11
HPV types 16 HPV types 18 HPV types 31 HPV types 33 HPV types 45 HPV types 52 HPV types 58 HPV types 6 |
| gptkbp:relatedTo |
gptkb:Gardasil
gptkb:Cervarix |
| gptkbp:routeOfAdministration |
intramuscular injection
|
| gptkbp:sideEffect |
fever
fatigue headache pain at injection site redness swelling |
| gptkbp:usedFor |
prevention of HPV infection
|
| gptkbp:WHOPrequalified |
yes
|
| gptkbp:bfsParent |
gptkb:Gardasil
|
| gptkbp:bfsLayer |
5
|